CervoMed Inc. (CRVO) Research

CervoMed Inc., headquartered in Boston, Massachusetts, operates as a clinical-stage biotechnology firm committed to discovering, developing, and ultimately bringing to market pharmaceutical solutions for various neurodegenerative conditions. A central component of their therapeutic pipeline is neflamapimod, an innovative small molecule designed for oral administration and capable of crossing the blood-brain barrier. This compound is currently being advanced as a potential treatment for debilitating ailments such as Lewy body dementia (DLB), Alzheimer's disease, and for aiding recovery following a cerebral stroke.

Market snapshot

Symbol
CRVO
Price
$4.24
Day change
+11.29%
Market cap
$39.3M
P/E ratio
-1.31x
52-week range
2.13-13.13
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$9.00

Peer companies

  • Adicet Bio, Inc. (ACET)
  • Adagene Inc. (ADAG)
  • Fortress Biotech, Inc. (FBIO)
  • Gain Therapeutics, Inc. (GANX)
  • Lite Strategy, Inc. (LITS)
  • NRx Pharmaceuticals, Inc. (NRXP)
  • Nutriband Inc. (NTRB)
  • OS Therapies Incorporated (OSTX)

Recent insider activity

  • BOGER JOSHUA S — P-Purchase (955414 shares) on 2026-06-11
  • BOGER JOSHUA S — P-Purchase (955414 shares) on 2026-06-11
  • BOGER JOSHUA S — P-Purchase (955414 shares) on 2026-06-11
  • ZAVRL FRANK — A-Award (8150 shares) on 2026-06-08
  • Sabbagh Marwan — A-Award (8150 shares) on 2026-06-08

Open CervoMed Inc. (CRVO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.